Ticker >

Chemo Pharma Labs share price

Chemo-Pharma Laboratories Ltd.

BSE: 506365 SECTOR: Pharmaceuticals & Drugs  4141   16   0

85.20
+2.60 (3.15%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 85.5

Today's Low

₹ 82.6

52 Week High

₹ 87

52 Week Low

₹ 27.17

FinStar is Suspended!

FinStar can not be assigned to this company due to its dicey outlook and insufficient data. We will update the FinStar for this company as soon as the data is updated from its end.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

12.78 Cr.

Enterprise Value

6.72 Cr.

No. of Shares

0.15 Cr.

P/E

9.5

P/B

0.98

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  87.3

CASH

6.06 Cr.

DEBT

0 Cr.

Promoter Holding

27.89 %

EPS (TTM)

₹  8.97

Sales Growth

0%

ROE

0.41 %

ROCE

0.74%

Profit Growth

-91.55 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 YearNA
3 YearNA
5 YearNA

Profit Growth

1 Year-91.55%
3 Year-51.52%
5 Year-14.01%

ROE%

1 Year0.41%
3 Year2.56%
5 Year2.73%

ROCE %

1 Year0.74%
3 Year2.28%
5 Year2.81%

Debt/Equity

0

Price to Cash Flow

-18.7

Interest Cover Ratio

6.63408251231527

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 27.89 0
Dec 2023 27.89 0
Sep 2023 27.89 0
Jun 2023 27.89 0
Mar 2023 27.89 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of 0 days.
  • Company has a healthy liquidity position with current ratio of 306.668134507606.

 Limitations

  • The company has shown a poor profit growth of -51.5203427784436% for the Past 3 years.
  • Company has a poor ROE of 2.5584891456547% over the past 3 years.
  • Company has a poor ROCE of 2.28107408567055% over the past 3 years
  • Company has negative cash flow from operations of -0.683447.
  • The company has a low EBITDA margin of 0% over the past 5 years.
  • The company is trading at a high PE of 9.5.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 0 0 0 0 0
Total Expenditure 0.02 0.02 0.05 0.02 0.02
Operating Profit -0.02 -0.02 -0.05 -0.02 -0.02
Other Income 0.19 -0.1 0.43 0.46 0.7
Interest 0 0 0 0 0
Depreciation 0 0 0 0 0
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.16 -0.12 0.38 0.44 0.68
Tax 0 0.03 0 0 0
Profit After Tax 0.16 -0.15 0.38 0.44 0.68
Adjusted EPS (Rs) 1.08 -0.99 2.51 2.93 4.51

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 0 0 0 0 0
Total Expenditure 0.56 0.48 0.33 0.5 0.61
Operating Profit -0.56 -0.48 -0.33 -0.5 -0.61
Other Income 0.82 1 0.67 0.88 0.71
Interest 0 0 0 0 0.01
Depreciation 0 0.02 0.02 0.02 0.01
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.25 0.49 0.31 0.36 0.07
Tax 0.05 0.08 0.06 -0.2 0.03
Net Profit 0.21 0.42 0.25 0.56 0.05
Adjusted EPS (Rs.) 1.38 2.77 1.67 3.73 0.32

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 1.5 1.5 1.5 1.5 1.5
Total Reserves 8.83 9.24 9.49 10.05 10.1
Borrowings 0 0 0 0 0
Other N/C liabilities 0 0 0 -0.26 -0.24
Current liabilities 0.09 0.22 0.06 0.11 0.02
Total Liabilities 10.42 10.97 11.05 11.4 11.38
Assets
Net Block 0 0.07 0.05 0.04 0.03
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0.04 0.02 0.04 2.94 3.03
Loans & Advances 1.84 1.96 0 2.12 2.2
Other N/C Assets 0 0 0 0 0
Current Assets 8.54 8.91 10.96 6.3 6.13
Total Assets 10.42 10.97 11.05 11.4 11.38
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 0.25 0.49 0.31 0.36 0.07
Adjustment -0.8 -0.97 -0.51 -0.65 -0.7
Changes in Assets & Liabilities -4.89 5.39 -0.13 0.02 -0.05
Tax Paid -0.05 -0.08 -0.09 -0.06 -0.01
Operating Cash Flow -5.48 4.83 -0.41 -0.33 -0.68
Investing Cash Flow 0.79 1.01 -0.19 0.97 0.63
Financing Cash Flow 0 0 1.96 -2.12 -0.08
Net Cash Flow -4.7 5.84 1.36 -1.49 -0.13

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 27.89 27.89 27.89 27.89 27.89
citric india ltd 24.63 24.63 24.63 24.63 24.63
shanta somani 3.25 3.25 3.25 3.25 3.25
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 72.11 72.11 72.11 72.11 72.11
ravindra somani 3.16 3.16 3.16 3.16 3.16
shree consultation and s... 3.63 3.63 3.63 3.63 3.63
sudhir harilal kale 2.33 2.33 2.33 2.33 2.33
llp 0.17 - - - -

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Chemo Pharma Laboratories informs about loss of share certificates23 Apr 2024, 4:59PM Chemo Pharma Labs - Quaterly Results29 Jan 2024, 5:17PM Chemo Pharma Labs - Quaterly Results29 Jan 2024, 5:17PM Chemo Pharma Labs - Quaterly Results29 Jan 2024, 5:17PM Chemo Pharma Labs - Quaterly Results27 Oct 2023, 5:19PM Chemo Pharma Labs - Quaterly Results27 Oct 2023, 5:19PM Chemo Pharma Labs - Quaterly Results27 Oct 2023, 5:19PM Chemo Pharma Laboratories informs about board meeting16 Oct 2023, 4:51PM Chemo Pharma Laboratories informs about declaration of non-applicability of disclosure 9 Oct 2023, 5:06PM Chemo Pharma Labs - Quaterly Results27 Jul 2023, 5:22PM Chemo Pharma Labs - Quaterly Results27 Jul 2023, 5:22PM Chemo Pharma Labs - Quaterly Results27 Jul 2023, 5:22PM Chemo Pharma Labs - Quaterly Results24 May 2023, 5:46PM Chemo Pharma Labs - Quaterly Results24 May 2023, 5:46PM Chemo Pharma Laboratories informs about board meeting15 May 2023, 4:17PM Chemo Pharma Laboratories informs about confirmation certificate10 Apr 2023, 5:01PM Chemo Pharma Laboratories informs about newspaper advertisement1 Feb 2023, 5:22PM Chemo Pharma Labs - Quaterly Results31 Jan 2023, 5:00PM Chemo Pharma Labs - Quaterly Results31 Jan 2023, 5:00PM Chemo Pharma Labs - Quaterly Results31 Jan 2023, 5:00PM Chemo Pharma Laboratories informs about trading window closure29 Dec 2022, 2:19PM Chemo Pharma Labs - Quaterly Results20 Oct 2022, 5:05PM Chemo Pharma Labs - Quaterly Results20 Oct 2022, 5:05PM Chemo Pharma Labs - Quaterly Results28 Jul 2022, 5:18PM Chemo Pharma Labs - Quaterly Results28 Jul 2022, 5:18PM Chemo Pharma Labs - Quaterly Results28 Jul 2022, 5:18PM Chemo Pharma Laboratories informs about compliances certificate4 Jul 2022, 5:07PM Chemo Pharma Laboratories informs about compliance certificate7 Apr 2022, 5:05PM Chemo Pharma Laboratories informs about compliances certificate 4 Jan 2022, 1:45PM Chemo Pharma Laboratories informs about voting results and scrutinizer’s report of AGM2 Sep 2021, 3:46PM Chemo Pharma Laboratories informs about appointment of additional director29 Jan 2021, 1:24PM Chemo-Pharma Laboratories informs about demise of chairman cum CEO 11 Nov 2020, 3:19PM Chemo-Pharma Laboratories submits annual report20 Aug 2020, 2:50PM

Chemo Pharma Labs Stock Price Analysis and Quick Research Report. Is Chemo Pharma Labs an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Chemo Pharma Labs and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Chemo Pharma Labs cash from the operating activity was Rs -0.683447 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Chemo Pharma Labs has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Chemo Pharma Labs , the EPS growth was -91.5508050041523 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Chemo Pharma Labs has OPM of 0 % which is a bad sign for profitability.
     
  • ROE: Chemo Pharma Labs have a poor ROE of 0.408546280694087 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Chemo Pharma Labs is Rs 85.2. One can use valuation calculators of ticker to know if Chemo Pharma Labs share price is undervalued or overvalued.
Last Updated on:
Brief about Chemo Pharma Labs
X